Taysha Gene Therapies (TSHA) remains a Buy on strong TSHA-102 Rett data, FDA-aligned pivotal path, and cash to 2028—read the ...
The new US Federal Reserve chair is shaking things up, but not all these changes bode well. Eliminating forward guidance has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results